Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.75 |
| ▸ | CNR1 | P21554 | 10/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.71 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.62 |
| ▸ | MLNR | O43193 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3813720 | 0.92 | CNR1 (0.74) | CNR2CNR1CYP2C9GPR55CYP1A2 | |
| Hydrochloric Acid SCHEMBL4604024 | 0.92 | CNR1 (0.74) | CNR2CNR1CYP2C9GPR55CYP1A2 | |
| SCHEMBL3814159 | 0.88 | CNR1 (0.72) | CNR2CNR1CYP2C9GPR55CYP1A2 | |
| SCHEMBL3817669 | 0.84 | CNR1 (0.71) | CNR2CNR1CYP2C9GPR55CYP1A2 | |
| SCHEMBL4831846 | 0.84 | CNR1 (0.71) | CNR2CNR1CYP2C9GPR55CYP1A2 | |
| SCHEMBL3814988 | 0.84 | CNR1 (0.71) | CNR2CNR1CYP2C9GPR55CYP1A2 | |
| SCHEMBL3815422 | 0.84 | CNR1 (0.64) | CNR2CNR1CYP2C9GPR55CYP1A2 | |
| SCHEMBL29835959 | 0.84 | CNR1 (1.00) | CNR2CNR1CYP2C9GPR55CYP1A2 | |
| SCHEMBL3815250 | 0.84 | CNR2 (0.91) | CNR2CNR1CYP2C9GPR55CYP1A2 | |
| SCHEMBL1517458 | 0.84 | CNR1 (1.00) | CNR2CNR1CYP2C9GPR55CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718617-B1 | 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | EP | claimed |
| US-20090149463-A1 | Therapeutic agents | CHENG LEIFENG | 2009-06-11 | — | — | US | claimed |
| EP-1915364-A1 | PYRAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | claimed |
| WO-2007020388-A1 | PYRAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | claimed |
| EP-1718617-B1 | 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | EP | disclosed |
| US-20090149463-A1 | Therapeutic agents | CHENG LEIFENG | 2009-06-11 | — | — | US | disclosed |
| EP-1915364-A1 | PYRAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007020388-A1 | PYRAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| EP-1718617-A2 | 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005080343-A2 | 3-SUBSTITUTED 1,5-DIPHENYLPYRAZOLE DERIVATIVES USEFUL AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149463-A1 | Therapeutic agents | NLN, BDNF, GAP43 | CNR2 209/4885CNR1 173/4885CYP2C9 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.